Resonance Health Limited
Research Resonance Health Limited (RHT.AX) on Bullrun: market cap AUD 36.26M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRHT.AX
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryHealth Information Services
- CurrencyAUD
- Market capAUD 36.26M
- Financial periodFY2025
Valuation Snapshot
latest market cap is AUD 36.26M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | n/a | n/a | n/a | 0 | n/a | n/a | n/a |
| FY2024 | AUD 8.59M | AUD 169.30K | AUD 1.01M | 100.0% | 0 | AUD 10.31M | AUD 3.70M | AUD 10.93M |
| FY2023 | AUD 4.40M | -AUD 780.36K | -AUD 624.93K | 100.0% | 0 | AUD 7.40M | AUD 272.95K | AUD 9.94M |
| FY2022 | AUD 3.83M | -AUD 1.14M | -AUD 2.16M | 100.0% | 0 | AUD 7.81M | AUD 268.22K | AUD 10.42M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-17 | AUD 36.26M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Resonance Health Limited
Resonance Health Limited, a healthcare technology and services company, designs, develops, manufactures, and commercializes software-as-medical devices (SaMD) in the Asia Pacific, North America, Europe, the Middle East, and Africa. It operates through SaMD, Resonance Clinical, and TrialsWest segments. The company offers FerriScan, a non-invasive MRI based solution for quantifying liver iron concentration (LIC); FerriSmart, an artificial intelligence (AI) solution for the automated real-time assessment of LIC;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Resonance Health Limited's market cap?
Resonance Health Limited's market capitalization is AUD 36.26M.
What does Resonance Health Limited do?
Resonance Health Limited, a healthcare technology and services company, designs, develops, manufactures, and commercializes software-as-medical devices (SaMD) in the Asia Pacific, North America, Europe, the Middle East, and Africa. It operates through SaMD, Resonance Clinical, and TrialsWest segments.